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Why we might not need to stress about ruling out inducible myocardial ischaemia  
Katy JL Bell1, Christopher Semsarian2,3,4, Jenny Doust5,  
In patients with symptoms of stable angina, cardiac stress testing and angiography have been 
recommended to evaluate for inducible myocardial ischaemia and obstructive coronary artery disease 
(CAD). In this issue of Annals of Internal Medicine, Walter et al investigate whether hs-cTn tests could be 
introduced as a new test in this diagnostic pathway. Because of their high sensitivity for detecting 
myocardial injury, negative hs-cTn tests are used to rule out acute coronary syndrome (ACS) in patients 
presenting with acute chest pain, allowing safe discharge home from the Emergency Department (their 
clinical utility for ruling in myocardial infarction is more uncertain(1)).  The authors of the current study 
hypothesised that hs-cTn tests could be used in a similar way in patients with stable angina, such that a 
negative result would safely rule out inducible myocardial ischemia without the need for further tests. 
They tested this hypothesis in a well conducted diagnostic accuracy study of 1,896 consecutive patients 
who had been referred to a single treatment centre for stress testing using myocardial perfusion single-
photon emission tomography/computer tomography (MPI-SPECT/CT). They measured hs-cTn using 
three different assays on blood samples taken before stress testing and processed by personnel blinded 
for clinical data. Adjudication of inducible myocardial ischemia was based on expert interpretation of 
MPI-SPECT/CT images for all 1,896 cases combined with information obtained from invasive coronary 
angiography and fractional flow reserve measurements in the 405 cases where this was available. The  
diagnostic  accuracy  of hs-cTn  to  identify  inducible myocardial ischemia was found to be low, with no 
cut-off level that provided the predefined minimum  negative predictive value and sensitivity of at least 
90% (defined on the basis of acceptable risk of false-negatives as a safety threshold (2)).  Patients with 
low pre-test probability (e.g.  <20% risk judged by treating clinician, women without hypertension, or 
women without previous MI) came close to meeting these specified criteria for ruling out disease 
without further testing, but they tended to represent only a small proportion of the study population 
(7%, <1% and 8% respectively).   
Under the current diagnostic pathway, patients with a positive stress test result are referred for an 
invasive coronary angiogram, and a decision made as to whether revascularization may be beneficial  - 
particularly if the patient is already on maximal anti-angina medical therapy. However, approximately 
half of patients with angina and an abnormal stress test do not have obstructive CAD on angiography, 
with women more likely to have a negative angiogram than men(3). The cause of symptoms in these 
patients may be coronary microvascular dysfunction, conduit arterial vessel stiffness, and/or diffuse 
atherosclerosis of both the macro and microvasculature. Optimising risk factor management through 
lifestyle change and medical therapy are the mainstays of treatment for non-obstructive CAD(3, 4). 
Recent evidence from randomised trials questions whether revascularisation via percutaneous coronary 
intervention (PCI) is beneficial even for patients with obstructive CAD, including those who have 
moderate or severe ischaemia on stress testing(5). Randomised controlled trials in patients with stable 
obstructive CAD who are on optimal medical therapy have found no evidence that PCI reduces the risk 
of an ischaemic event(5-7), or that it reduces symptoms beyond that of a sham procedure(8). This raises 
the question of whether symptoms of stable CAD have been wrongly attributed to obstructive CAD 
found on tests, when the non-obstructive CAD causes outlined above may be the true culprits(4). The 
evidence for benefit from detection of obstructive CAD and subsequent revascularization is clear in 
patients with acute coronary syndromes, and in patients with severe stenosis of the left main coronary 
artery. There is also evidence that in selected patients with stable CAD on optimal medical therapy, 
revascularisation via coronary artery bypass grafting (CABG) reduces the risk of myocardial infarction – 
perhaps reflecting treatment of atherosclerotic plaques throughout the diseased vessel rather than just 
a discrete lesion(4).  
So how do we interpret the findings of the current study on hs-cTn, in light of the limited clinical utility 
of identifying inducible myocardial ischaemia and obstructive CAD? In the setting of imperfect reference 
standards, the concept of the ‘Fair Umpire’ may help to work out when a new test may be better than 
the existing test(9). The clinical consequences of the new test can be understood by applying a ‘fair 
umpire’ test to cases where the old and new tests disagree. In this case, we want to apply the fair 
umpire to people with a positive Hs-cTn result and negative stress test/angiogram, or with negative hs-
cTn result and positive stress test/negative angiogram. The study presents data on an umpire test that 
we can use to assess the implications of the discordant test results in these people: prognosis/risk of 
adverse clinical outcomes. In both patients with and without inducible myocardial ischemia, higher hs-
cTn concentrations were associated with a higher cumulative incidence  of cardiovascular death, all-
cause-death, and non-fatal AMI. From the Kaplan Meier curves presented, a positive result for inducible 
ischemia appeared to add to the prediction of revascularisation beyond hs-cTn level, likely reflecting the 
influence of this result on the decision for revascularisation (operators weren’t blinded to results for 
inducible ischemia). For cardiovascular death and all-cause death, the curves show larger differences 
across hs-cTn quartiles than between inducible vs non-inducible ischaemia test results, suggesting that 
hs-cTn may in fact be a better prognostic test in patients with stable CAD than the existing stress 
test/angiogram reference standard. This prognostic ability is supported by the findings of a recently 
published study that included >240,000 patients without ACS, and found strong associations between 
troponin levels and mortality(10).  
If identifying a coronary artery stenosis for revascularisation does not benefit the patient with stable 
CAD, but may cause them harm (through complications of PCI), then is it a diagnosis we actually want to 
make? Walter et al conclude that hs-cTn cannot safely exclude inducible myocardial ischemia, and by 
implication stable obstructive CAD, but the bigger question is whether that needs excluding in the first 
place. Rather, should the focus of testing in patients with stable CAD be on safely ruling out significant 
pathology such as left main artery disease (revascularisation likely to have net benefit), while preventing 
unnecessary invasive tests and interventions in the majority (likely to have net harm)? Whether hs-cTn 
has a role in such a triage process at this point remains unclear. 
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